# EDGAR Filing Document

**Accession Number:** 0001725160
**File Stem:** 0001725160-26-000049
**Filing Date:** 2026-5
**Character Count:** 7732
**Document Hash:** b20d11732f90a0bbf2ecc2fa589eafef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001725160-26-000049.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0001725160-26-000049

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260522

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zentalis Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001725160
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823607803
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39263
- **FILM NUMBER:** 261026183

**BUSINESS ADDRESS:**
- **STREET 1:** 10275 SCIENCE CENTER DRIVE
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 263-4333

**MAIL ADDRESS:**
- **STREET 1:** 10275 SCIENCE CENTER DRIVE
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zentalis Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20200107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zeno Pharma, LLC
- **DATE OF NAME CHANGE:** 20171212

?xml version='1.0' encoding='ASCII'? zntl-20260522

    

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**——————————————**

**FORM 8-K**

**——————————————**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of report (Date of earliest event reported): May 22, 2026**

**——————————————** 

**ZENTALIS PHARMACEUTICALS, INC.** 

**(Exact name of registrant as specified in its charter)** 

**——————————————**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39263** | **82-3607803** |
| **(State or other jurisdiction**<br>**of incorporation or organization)** | **(Commission**<br>**File Number)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**10275 Science Center Drive, Suite 200** 

 **San Diego, California 92121**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(Address of principal executive offices) (Zip Code)** 

**(858) 263-4333**

**(Registrant's telephone number, include area code)** 

 **N/A**

**(Former name or former address, if changed since last report)** 

**——————————————**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

------

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | ZNTL | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective May 22, 2026, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director. Ms. Campbell's initial term is scheduled to expire at the Company's 2027 Annual Meeting of Stockholders, subject to the election and qualification of her successor and her earlier death, resignation or removal. Ms. Campbell has also been appointed to serve on the Compensation Committee of the Board (the "Compensation Committee").

There is no arrangement or understanding between Ms. Campbell and any other person pursuant to which she was appointed as a director of the Company, and there are no family relationships between Ms. Campbell and any of the Company's directors or executive officers. There are no transactions to which the Company is a party and in which Ms. Campbell has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.

Ms. Campbell is entitled to receive compensation for her service as a director in accordance with the Company's Non-Employee Director Compensation Program applicable to all non-employee directors (the "Director Compensation Program"), which provides for an annual retainer of $45,000 for her Board service, and additional annual retainer of $7,500 for her service as a member of the Compensation Committee.

In accordance with the Director Compensation Program, as a new non-employee director, Ms. Campbell was granted restricted stock units ("RSUs") covering 114,200 shares of the Company's common stock on May 26, 2026, which number of shares was determined by multiplying (i) the number of common shares outstanding as of the day prior to the date of grant, by (ii) 0.16% (such percentage determined by the board). The initial RSU grant vests over three years with one-third of the underlying shares vesting on each of the first, second and third anniversaries of the date of grant.

Also in accordance with the Director Compensation Program, after Ms. Campbell has served on the Board for at least six months, Ms. Campbell is entitled to receive an annual equity grant on the date of the Company's next annual meeting of stockholders of RSUs covering that number of shares of the Company's common stock as is determined by multiplying (i) the number of common shares outstanding as of the day prior to the date of grant, by (ii) 0.08%. Annual RSU awards granted to non-employee directors vest in full on the first to occur of (i) the first anniversary of the applicable grant date, and (ii) the next occurring annual meeting of the Company's stockholders.

Pursuant to the Director Compensation Program, the initial and annual equity awards granted to Ms. Campbell under the Director Compensation Program vest in full upon a change in control and, in each case, are subject to Ms. Campbell's continued service through the applicable vesting date.

Ms. Campbell has also entered into the Company's standard indemnification agreement for directors and officers, the form of which is included as Exhibit 10.6 to the Company's Annual Report on Form 10-K filed on March 26, 2026.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | ZENTALIS PHARMACEUTICALS, INC. | ZENTALIS PHARMACEUTICALS, INC. |
| Date: May 27, 2026 | By: | /s/ Julie Eastland |
|  |  | Julie Eastland |
|  |  | President and Chief Executive Officer |

---